Most patients with peripheral t-cell lymphoma ultimately face the choice of bone marrow transplantation. 1. Peripheral T-cell lymphoma (PTCL) is a malignant clonal disease of mature T-cells, which is more common in China, with a higher incidence than that in Europe and the United States. It is highly aggressive, progresses rapidly, has a low percentage of early stage, is insensitive to chemotherapeutic drugs, and is prone to recurring, with poor efficacy of existing treatments and no standard first-line regimen yet, and with overall poor prognosis, unsatisfactory long-term survival, and high therapeutic difficulty. 2. Once PTCL recurs, the prognosis is extremely poor. In addition to chemotherapy, bone marrow transplantation is a commonly used treatment option in China. Usually, after the first-line chemotherapy, the patient reaches complete remission, and autologous hematopoietic stem cell transplantation is often given to consolidate the treatment and realize the effective prolongation of the patient’s survival time. For patients with refractory relapse, chemotherapy insensitivity, repeated progression after chemotherapy or bone marrow infiltration, allogeneic HSCT is considered. 3. Internationally, there are still cutting-edge programs that have not yet been introduced domestically, and optimized multiple combination or single-drug programs are still being explored domestically, and the research data are relatively optimistic. Patients are advised to go to the hospital in time.